First-line (1L) osimertinib plus platinum-pemetrexed in EGFRmutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results

被引：0
|
作者：
Planchard, D. [1 ]
Poltoratskiy, A. [2 ]
Kim, S-W. [3 ]
Kim, T. M. [4 ]
Yanagitani, N. [5 ]
Kagamu, H. [6 ]
Feng, P-H. [7 ]
Hughes, B. [8 ]
Yang, T-Y. [9 ]
Yang, J. C-H. [10 ,11 ]
Lee, C. K. [12 ]
Karaseva, N. [13 ]
Mitchell, P. [14 ]
Tambo, Y. [15 ]
Monterroso, E. Armenteros [16 ]
Todd, A. [17 ]
Sahasrabudhe, A. [18 ]
Janne, P. A. [19 ]
Kobayashi, K. [20 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France
[2] Petrov Res Inst Oncol, Dept Preclin & Clin Trials, St Petersburg, Russia
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan
[6] Saitama Med Univ, Dept Gen Surg, Saitama, Japan
[7] Taipei Med Univ, Shuang Ho Hosp, Div Pulm Med, Dept Internal Med, Taipei, Taiwan
[8] Prince Charles Hosp, Dept Canc Care Serv, Herston, Qld, Australia
[9] Taichung Vet Gen Hosp, Dept Pulm Med, Taichung, Taiwan
[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[12] St George Hosp, Dept Med Oncol, Canc Care Ctr, Kogarah, NSW, Australia
[13] City Clin Oncol Hosp, Thorac Dept, St Petersburg, Russia
[14] Austin Hlth, Olivia Newton John Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[15] Kanazawa Univ Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan
[16] AstraZeneca, Late Dev Oncol R&D, Cambridge, England
[17] AstraZeneca, Oncol Biometr, Cambridge, England
[18] AstraZeneca, Dept Patient Safety Oncol, Cambridge, England
[19] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Dept Med Oncol, Boston, MA 02115 USA
[20] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.646
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
568P
引用
收藏
页码：S1692 / S1693
页数：2
相关论文
共 50 条
  • [21] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie P. L.
    Low, Yi Fen
    Lai, Gillianne G. Y.
    Chan, Landon L.
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia H.
    Seet, Amanda O. L.
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan -Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren W. T.
    Tan, Daniel S. W.
    Mok, Tony S. K.
    Li, Molly S. C.
    LUNG CANCER, 2024, 193
  • [22] ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
    Piotrowska, Z.
    Ahn, M-J.
    Pang, Y. K.
    How, S. H.
    Kim, S-W.
    Voon, P. J.
    Cortinovis, D. L.
    De Castro Carpeno, J.
    Tiseo, M.
    Rodriguez Abreu, D.
    Ramalingam, S. S.
    Li, J.
    Servidio, L.
    Sadow, S.
    Hartmaier, R. J.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1420 - S1421
  • [23] ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
    Piotrowska, Z.
    Ahn, M-J.
    Pang, Y-K.
    How, S. H.
    Sang-We, K.
    Voon, P. J.
    Cortinovis, D. L.
    Carpeno, J. De Castro
    Tiseo, M.
    Abreu, D. Rodriguez
    Ramalingam, S. S.
    Li, J.
    Servidio, L.
    Sadow, S.
    Hartmaier, R. J.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1581 - S1582
  • [24] Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study
    Ahn, M-J.
    Cho, B. C.
    Pang, Y. K.
    Voon, P. J.
    Kim, S-W.
    De Castro Carpeno, J.
    Tiseo, M.
    Li, J.
    Servidio, L.
    Sadow, S.
    Markovets, A.
    Tang, K. H.
    Piotrowska, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1563 - S1564
  • [25] Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Balmanoukian, Ani Sarkis
    Kim, Dong-Wan
    Kim, Sang-We
    Ahn, Myung-Ju
    Jamal, Rahima
    Jaeger, Dirk
    Ott, Patrick Alexander
    Ascierto, Paolo Antonio
    Gregorc, Vanesa
    Goldman, Jonathan Wade
    Blakely, Collin M.
    Jin, Xiaoping
    Antal, Joyce
    Gupta, Ashok Kumar
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
    De Langen, J.
    Cho, B. C.
    Piotrowska, Z.
    Le, X.
    Goldberg, S. B.
    Goldman, J. W.
    Okamoto, I.
    Hewson, N.
    Maidment, J.
    Tang, K. H.
    Veney, N.
    Cosaert, J.
    Lau, J.
    Dressman, M.
    Ambrose, H.
    Riess, J. W.
    Yu, H. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1091 - S1092
  • [27] CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC
    Paz-Ares, L.
    Urban, L.
    Audigier-Valette, C.
    Grossi, F.
    Jao, K.
    Aucoin, J.
    Linardou, H.
    Poddubskaya, E. Vladimirovna
    Fischer, J.
    Fontecedro, A. Curioni
    Groen, H.
    Vermaelen, K.
    Bourhaba, M.
    Kowalski, D.
    Pillai, R.
    Spigel, D.
    Ahmed, S.
    Hu, W.
    Vickery, D.
    Fiore, J.
    Ready, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S493 - S493
  • [28] First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results.
    Yanez, Patricio Eduardo
    Ben-Aharon, Irit
    Rojas, Carlos
    Eyzaguirre, Daniel Acosta
    Hubert, Ayala
    Araya, Hernan
    Cohen, Deirdre Jill
    Bai, Li-Yuan
    Ghiringhelli, Francois
    Wyrwicz, Lucjan
    Janjigian, Yelena Y.
    Tabernero, Josep
    Van Cutsem, Eric
    Qin, Shukui
    Xu, Jianming
    Wang, Anran
    Miller, Mary Gwen
    Shih, Chie-Schin
    Bhagia, Pooja
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 411 - 411
  • [29] Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study
    Yang, Y.
    Wang, Z.
    Fang, J.
    Yu, Q.
    Han, B.
    Cang, S.
    Chen, G.
    Mei, X.
    Yang, Z.
    Stefaniak, V.
    Lin, Y.
    Wang, S.
    Zhang, W.
    Sun, L.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S28 - S28
  • [30] Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
    Ramalingam, S.
    Yang, J. C. -H.
    Lee, C. K.
    Kurata, T.
    Kim, D. -W.
    John, T.
    Nogami, N.
    Ohe, Y.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S152 - S152
12345